Sienna Biopharmaceuticals is a clinical-stage biopharmaceutical company. Co.'s primary product candidates from its technological platform are SNA-120 (pegcantratinib), a first-in-class TrkA inhibitor for the topical treatment of psoriasis, as well as the associated pruritus; and SNA-125, a topical JAK3/TrkA inhibitor with the potential to treat various inflammatory conditions, including atopic dermatitis, psoriasis and the associated pruritus. Co.'s second technology platform, Topical Photoparticle Therapy™, utilizes silver particles applied to the skin to direct the light from commercially available lasers to the hair follicle or sebaceous gland to cause selective photothermolysis. We show 12 historical shares outstanding datapoints in our coverage of SNNA's shares outstanding history.
Understanding the changing numbers of SNNA shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SNNA versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SNNA by allowing them to research SNNA shares outstanding history
as well as any other stock in our coverage universe. |
Free SNNA Email Alerts:
Video: Shares Outstanding Importance
